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Glycogen synthase kinase-3 negatively regulates anti-inflammatory
interleukin-10 for lipopolysaccharide-induced iNOS/NO biosynthesis
and RANTES production in microglial cells
Introduction
Patients with bacteraemia caused by a microbial infection
may develop life-threatening septic shock after multiple
organ failure or multiple organ dysfunction syndrome
(MOF/MODS).1,2 Inpatients with MOF/MODS have a
25–50% higher mortality rate than those without MOF/
MODS.3–6 The progression and severity of septic MOF/
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Summary
The inflammatory effects of glycogen synthase kinase-3 (GSK-3) have
been identified; however, the potential mechanism is still controversial. In
this study, we investigated the effects of GSK-3-mediated interleukin-10
(IL-10) inhibition on lipopolysaccharide (LPS)-induced inflammation.
Treatment with GSK-3 inhibitor significantly blocked LPS-induced nitric
oxide (NO) production as well as inducible NO synthase (iNOS) expres-
sion in BV2 murine microglial cells and primary rat microglia-enriched
cultures. Using an antibody array and enzyme-linked immunosorbent
assay, we found that GSK-3-inhibitor treatment blocked LPS-induced
upregulation of regulated on activation normal T-cell expressed and
secreted (RANTES) and increased IL-10 expression. The time kinetics and
dose–response relations were confirmed. Reverse transcription–polymerase
chain reaction showed changes on the messenger RNA level as well. Inhib-
iting GSK-3 using short-interference RNA, and transfecting cells with
dominant-negative GSK-3b, blocked LPS-elicited NO and RANTES
expression but increased IL-10 expression. In contrast, GSK-3b over-
expression upregulated NO and RANTES but downregulated IL-10 in
LPS-stimulated cells. Treating cells with anti-IL-10 neutralizing antibodies
to prevent GSK-3 from downregulating NO and RANTES showed that the
anti-inflammatory effects are, at least in part, IL-10-dependent. The
involvement of Akt, extracellular signal-regulated kinase, p38 mitogen-
activated protein kinase and nuclear factor-jB that positively regulated
IL-10 was demonstrated. Furthermore, inhibiting GSK-3 increased the
nuclear translocation of transcription factors, that all important for IL-10
expression, including CCAAT/enhancer-binding protein beat (C/EBPb),
C/EBPd, cAMP response binding element protein and NF-jB. Taken
together, these findings reveal that LPS induces iNOS/NO biosynthesis
and RANTES production through a mechanism involving GSK-3-mediated
IL-10 downregulation.
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I M M U N O L O G Y O R I G I N A L A R T I C L E
MODS seems to depend more on the host response fol-
lowed by immunopathogenesis.7–9 Inflammatory endo-
toxaemia causes uncontrolled systemic inflammatory
activation, coagulopathy, cytokine and chemokine over-
production and deregulated cell apoptosis.10–14
The endotoxin lipopolysaccharide (LPS), the microbial
component of Gram-negative bacteria, causes multiple
inflammatory and apoptotic responses that may induce
systemic septic dysfunction in MOF/MODS, including
vasculopathy, neurocytotoxicity and renal failure.8,15–17
Both are major causes of mortality from inflammation
and tissue damage in severe sepsis. Monocytes and
macrophages, neutrophils, B lymphocytes, dendritic cells
and epithelial and endothelial cells are the targets of LPS
because of the expression of receptors such as CD14,
Toll-like receptor (TLR) and Mac-1 (CD18/CD11b) for
LPS binding.18 Microglia, derived macrophages in the
brain, are also highly responsive to LPS.19,20 Unfortu-
nately, these cells markedly overproduce cytokines, e.g.
tumour necrosis factor-a (TNF-a) and interleukin-1
(IL-1), or chemokines, or both, after LPS stimulation.9
The proinflammatory cytokines TNF-a and IL-1 induce
the production of other cytokines (IL-6, IL-10 and
IL-12), chemokines [IL-8, regulated on activation normal
T-cell expressed and secreted (RANTES) and monocyte
chemotactic protein (MCP-1)] and inflammatory media-
tors, such as adhesion molecules, platelet-activating factor,
nitric oxide (NO) and oxygen free radicals.2,7–9,21 The
excessive production of NO by inducible NO synthase
(iNOS) in LPS-stimulated and cytokine-stimulated host
cells, particularly macrophages, contributes to circulatory
failure.2,6,22
Interleukin-10, a potent anti-inflammatory cytokine,
inhibits the synthesis of the proinflammatory cytokines
[TNF-a, IL-1, IL-6, IL-12, IL-18, granulocyte–macrophage
colony-stimulating factor (GM-CSF) and IL-10 itself] and
chemokines [IL-8, interferon inducible protein-10 (IP-10)
macrophage inflammatory protein (MIP-2), MCP-1 and
RANTES].23,24 Meanwhile, IL-10 potently modulates the
production of soluble mediators in inflammation, such as
platelet-activating factor and prostaglandins. Immuno-
modulatory IL-10 therefore has the clinical benefit of
downregulating inflammation and cell-mediated immune
responses. The exogenous administration of IL-10 and the
endogenous upregulation of IL-10 using gene therapy and
IL-10 upregulatory agents protect mice in an animal
model of LPS-induced sepsis.25–27 Interleukin-10 limits
and terminates inflammatory responses in endotoxaemic
patients.28–30 Clinical trials with recombinant IL-10 indi-
cate that it may be therapeutic against MOF/MODS by
improving outcomes in septic syndromes such as acute
respiratory failure and Crohn’s disease.
Recent studies31,32 report that inhibiting glycogen syn-
thase kinase-3 (GSK-3), originally identified as a key
enzyme regulating glycogen synthesis, downregulates
TLR-mediated inflammatory responses but increases
IL-10 production. Furthermore, inhibiting GSK-3 protects
cells against TNF-a, endotoxaemia, experimental coli-
tis, type II collagen-induced arthritis, zymosan and
ovalbumin-induced asthma.31,33–39 The anti-inflammatory
properties and mechanisms of inhibiting GSK-3 are
widely speculated about and may be useful for ameliorat-
ing endotoxin-mediated inflammatory diseases as well as
preventing endotoxaemia from developing into severe
sepsis.32,40–42 In the present study, we show that GSK-3
negatively regulates anti-inflammatory IL-10 for LPS-
induced iNOS/NO biosynthesis and RANTES production
in microglial cells. The mechanism of IL-10 upregulation
by inhibiting GSK-3 is also investigated.
Materials and methods
Antibodies and reagents
Rabbit polyclonal antibodies specific for nuclear factor-jB
(NF-jB) p65, and mouse monoclonal antibody to
b-actin, were purchased from Chemicon International,
Inc. (Temecula, CA). BD PharMingen monoclonal anti-
mouse iNOS was from Becton Dickinson Biosciences
(Palo Alto, CA). Neutralizing anti-IL-10 was from R&D
Systems (Minneapolis, MN). Alexa Fluor 488- and horse-
radish peroxidase (HRP)-conjugated goat anti-mouse or
anti-rabbit immunoglobulin G were from Invitrogen
Corp. (Carlsbad, CA). Goat anti-mouse GSK-3b, rabbit
anti-mouse Sp1, cAMP response binding element protein
(CREB), CCAAT/enhancer-binding protein beat (C/EBPb)
and C/EBPd were obtained from Santa Cruz Biotechno-
logy (Santa Cruz, CA). Rabbit anti-mouse GSK-3b (Ser9),
Akt (Ser473), Akt, extracellular signal-regulated kinase
(ERK; Thr202/Tyr204), ERK, p38 mitogen-activated pro-
tein kinase (MAPK; Thr180/Tyr182) and p38 MAPK were
purchased from Cell Signaling Technology, Inc. (Beverly,
MA). The LPS from Escherichia coli strain O111:B4 was
purchased from Calbiochem (San Diego, CA). The GSK-3
inhibitors lithium chloride (LiCl), thiadiazolidine
(TDZD-8), SB216763, SB415286, AR-A014418, 6-bromo-
indirubin-30-oxime (BIO), GSK-3 inhibitor I and
LY294002, U0126, SB203580, pyrrolidine dithiocarbamate
(PDTC) and other chemical reagents were obtained from
Sigma-Aldrich Co. (St Louis, MO).
Cell culture
BV2 immortalized murine microglial cells were obtained
from Dr C. C. Huang (Department of Pediatrics, National
Cheng Kung University, Tainan, Taiwan). Primary rat
microglia-enriched cultures with a purity of > 98% were
prepared from whole brains of 1-day-old Sprague-Dawley
breeder rat pups as previously described.43 Cells were
grown in Dulbecco’s modified Eagle’s minimal essential
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medium (DMEM) supplemented with 10% heat-inacti-
vated fetal bovine serum (FBS), 50 U/ml penicillin and
50 lg/ml streptomycin in a humidified atmosphere with
5% CO2 and 95% air.
Nitrite assay
We assessed NO production by measuring the accumu-
lated levels of nitrite in the supernatant with the Griess
reagent as previously described.43 Briefly, 100 ll of the
culture supernatant was reacted with 100 ll Griess
reagent (1% sulphanilamide, 01% naphthylethylenedi-
amine dihydrochloride and 25% H3PO4) for 10 min at
room temperature. The concentration of nitrite was mea-
sured using spectrophotometry (Spectra MAX 340PC;
Molecular Devices Corporation, Sunnyvale, CA) at
540 nm, and the nitrite concentration was calculated
using a standard curve of sodium nitrite with ELISA soft-
ware (Softmax Pro; Molecular Devices).
Reverse transcription–polymerase chain reaction
We assessed messenger RNA (mRNA) expression using
reverse transcription–polymerase chain reaction (RT-
PCR). Total cellular RNA from cells was extracted using a
reagent (Trizol; Invitrogen) according to the manufac-
turer’s instructions. We quantified RNA concentrations
using spectrophotometry at 260 nm (U-2000; Hitachi,
Tokyo, Japan). Complementary DNA was prepared using
reverse transcription, and PCR was performed using a
thermal cycler (GeneAmp PCR system 2400; PerkinElmer,
Fremont, CA). We used the following oligonucleotide
primers for:
Mouse iNOS – sense: 50-CCCTTCCGAAGTTTCTGG
CAGCAGCG-30 and antisense: 50-GGCTGTCAGAGCCT
CGTGGCTTTGG-30; RANTES – sense: 50-ATATGGCT
CGGACACCACTC-30 and antisense: 50-CCCACTTCTTC
TCTGGGTTG-30; IL-10 – sense: 50-ACCTGGTAGAAG
TGATGCCCCAGGCA-30 and antisense: 50-CTATGCAGT
TGATGAAGATGTCAAA-30; and b-actin – sense: 50-TGG
AATCCTGTGGCATCCATGAAAC-30 and antisense:
50-TAAAACGCAGCTCAGTAACAGTCCG-30.
The PCR products were analysed using 15% agarose
gel electrophoresis, stained with ethidium bromide, and
viewed with ultraviolet light. The expression of mRNA
was quantified using densitometry with LABWORKS IMAGE
ACQUISITION AND ANALYSIS Software (UVP, Upland, CA).
Western blot analysis
We harvested the cells and lysed them with a buffer con-
taining 1% Triton X-100, 50 mM Tris–HCl (pH 75),
10 mM ethylenediaminetetraacetic acid (EDTA), 002%
NaN3 and a protease inhibitor cocktail (Roche Boehringer
Mannheim Diagnostics, Mannheim, Germany). After they
had been freeze–thawed once, the cell lysates were centri-
fuged at 13 400 g at 4 for 20 min. In addition, the
nuclear lysates were prepared using a compartment Proteo-
Extract Subcellular Proteome Extraction Kit (Calbio-
chem) according to the manufacturer’s instructions. The
lysates were then collected and boiled in sample buffer for
5 min. After they had undergone sodium dodecyl sul-
phate–polyacrylamide gel electrophoresis, proteins were
transferred to PVDF membrane (Millipore, Billerica, MA),
blocked at 4 overnight in PBS-T (PBS plus 005% Tween-
20) containing 5% skimmed milk, and probed with pri-
mary antibodies at 4 overnight. After they had been
washed with PBS-T, blots were incubated with a 1 : 5000
dilution of HRP-conjugated secondary antibodies at 4 for
1 hr. The protein bands were visualized using enhanced
chemiluminescence (Pierce Biotechnology Inc., Rockford,
IL) and the relative signal intensity was quantified using
densitometry with LABWORKS ANALYSIS software (UVP).
Flow cytometric analysis
The cells were detached using 1000 U/ml trypsin and
05 mM EDTA. Suspensory cells were fixed and permeabi-
lized using a kit (BD PharMingen Cytofix/Cytoperm;
Becton Dickinson Biosciences). Antibodies specific for
iNOS were added to the cells and incubated at 4 for
1 hr. After they had been washed with PBS, the cells were
incubated with Alexa Fluor 488-conjugated secondary
antibodies at 4 for 1 hr. After they had been washed
with PBS, cells were analysed using flow cytometry with
excitation set at 488 nm (FACSCalibur; BD Biosciences).
Cytokine antibody array studies
The profile of cytokine production was determined using
a cytokine antibody array (Mouse Cytokine Antibody
Array III M0308003; RayBiotech, Inc., Norcross, GA)
according to the manufacturer’s instructions. Briefly,
100 lg/ml of protein from cell-conditioned culture med-
ium was incubated with the array membrane at 4 for
1 hr. After they had been washed with PBS, membrane
was then incubated with primary biotin-conjugated anti-
bodies and HRP-conjugated streptavidin. Signals were
detected using enhanced chemiluminescence and the rela-
tive signal intensity was quantified using densitometry
with LABWORKS ANALYSIS software (UVP) with reference to
the positive controls on the membrane.
Enzyme-linked immunosorbent assay
The concentrations of IL-10 and RANTES in cell-condi-
tioned culture medium and mouse sera were determined
using enzyme-linked immunosorbent assay (ELISA) kits
(R&D Systems) according to the manufacturer’s instruc-
tions.
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GSK-3b overexpression
The pcDNA 3.1 constructs expressing pEGFP, pEGFP-
GSK-3b wild-type (GSK-3b WT) and pEGFP-GSK-3b
dominant-negative (GSK-3b DN), an enzymatically inert
GSK-3b mutant (R96A), were gifts from Dr P. J. Lu
(Institute of Clinical Medicine, College of Medicine,
National Cheng Kung University, Tainan, Taiwan). For
transfection, cells were seeded in 24-well plates on cover-
slips and grown to 60–80% confluence for 24 hr. The
cells were then exposed to a mixture of 2 ll Lipofect-
AMINE 2000 (Invitrogen Life Technologies) and 2 lg
plasmid DNA for 6 hr in serum-free medium, after
which full culture medium was added. The transfection
efficiency was monitored by flow cytometry.
GSK-3 short interference RNA
GSK-3a/b expression was silenced using GSK-3 short
interference RNA (siRNA) kits according to the manufac-
turers’ instructions (Cell Signaling Technology and
Upstate Biotechnology, Charlottesville, VA). Briefly,
before short-hairpin RNA transfection, 106 cells were
washed with serum-free DMEM and then cultured with
2 ll LipofectAMINE 2000 and various doses of siRNA in
24-well plates. By flow cytometric analysis, a fluorescein
isothiocyanate-labelled non-targeted negative control si-
RNA was used to monitor the efficiency of siRNA trans-
fection. After 6 hr of incubation, the cells were washed
with DMEM containing 10% FBS and maintained for an
additional 24 hr before the experiments.
Statistical analysis
Data were analysed using the Student’s t-test with com-
mercially available statistical software (SIGMAPLOT 8.0 for
Windows; Systat Software, Inc., San Jose, CA). Statistical
significance was set at P < 005.
Results
LPS activated GSK-3 and inhibiting GSK-3 reduced
LPS-induced NO production and iNOS expression
To investigate the role of GSK-3 in LPS-induced inflam-
mation, we first examined the activation of GSK-3 in
LPS-stimulated BV2 mouse microglial cells. Western blot
analysis showed that LPS caused GSK-3b dephosphoryla-
tion at Ser9, a critical residue for inactivation of GSK-3b
while it was phosphorylated44,45 (Fig. 1a). BV2 cells trea-
ted with 1 lg/ml LPS for 24 hr showed significantly
(P < 005) higher NO production than did control cells
(data not shown). We then tested the effects of the GSK-3
inhibitors LiCl, TDZD-8, SB216763, SB415286, AR-
A014418, BIO and GSK-3 inhibitor I on LPS-induced NO
production. All GSK-3 inhibitors significantly (P < 005)
reduced LPS-induced NO production in mouse BV2
(Fig. 1b, left panel) and primary rat microglia-enriched
cells (Fig. 1b, right panel). These results strongly indicated
that GSK-3 was essential for enabling LPS-induced NO
production. The mechanisms through which NO produc-
tion is downregulated require further investigation.
Biosynthesis of iNOS usually regulates NO production
in microglia. To verify that the mechanisms inhibiting
GSK-3 cause NO reduction, we further studied iNOS
mRNA and protein expression in LPS-treated BV2 micro-
glial cells. We found, using RT-PCR, that LiCl and BIO
inhibited iNOS mRNA (data not shown) and, using
Western blotting, that LiCl and BIO inhibited iNOS
protein expression (Fig. 1c). Immunocytochemical stain-
ing and then flow cytometric analysis yielded similar
results: cells treated with BIO showed lower iNOS protein
expression (Fig. 1d). Taken together, these results
provided strong evidence that inhibiting GSK-3 down-
regulated iNOS expression, thereby reducing NO produc-
tion in LPS-treated microglia.
Inhibiting GSK-3 regulated LPS-induced cytokine and
chemokine production
Inhibiting GSK-3 decreases the inflammatory cytokines
TNF-a, IL-6 and IL-12, and increases the anti-inflamma-
tory cytokine IL-10 in TLR-mediated inflammation.31 To
identify the effects of inhibiting GSK-3 on the other inflam-
matory factors upregulated by LPS/TLR-4-mediated signal-
ling, we treated cells with LPS and with or without GSK-3
inhibitors. We then evaluated cytokine expression using a
cytokine antibody array kit. A series of cyokines including
CXCL16, eotaxin, eotaxin-2, granulocyte CSF, GM-CSF,
IL-1a, IL-6, IL-9, MCP-1, MIP-1a, MIP-c, MIP-2, RAN-
TES, TNF-a, soluble TNF receptor I (sTNF RI) and sTNF
RII were upregulated in LPS-treated BV2 cells (data not
shown). Treating cells with LiCl or BIO effectively inhibited
LPS-upregulated cytokines except GM-CSF, IL-6, MCP-1,
MIP-1a, MIP-2, sTNF RI and sTNF RII (data not shown).
Co-treatment with LiCl or BIO significantly (P < 005)
reduced LPS-induced RANTES production (666 ± 318
with LPS only versus 459 ± 002 with LPS + LiCl and
492 ± 238 with LPS + BIO) (Fig. 2a). To confirm these
effects and previous results, further results using ELISA
showed the time kinetics (Fig. 2b) and dose–response
(Fig. 2c) of GSK-3 inhibition on RANTES and IL-10 pro-
duction. The RT-PCR analysis of the effects of inhibiting
GSK-3 on RANTES mRNA and IL-10 mRNA expression
showed that RANTES was lower in LPS-treated cells 3 hr
after GSK-3-inhibitor co-treatment (157 with LPS only
versus 051 with LPS + LiCl and 072 with LPS + BIO) but
that IL-10 mRNA was higher (012 with LPS only versus
037 with LPS + LiCl and 102 with LPS + BIO) 05 hr
after LPS stimulation (Fig. 2d).
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Effects of GSK-3b in LPS-induced NO, RANTES and
IL-10 production
To exclude the indeterminate effects of GSK-3 inhibitors,
we silenced GSK-3 expression using siRNA and then
investigated the effects on the production of LPS-induced
NO, RANTES and IL-10. The rates of transfection effi-
ciency were 902% and 875%, respectively, in the control
and GSK-3 siRNA groups (data not shown). Western blot
analysis showed downregulated GSK-3b expression in the
GSK-3 siRNA group (Fig. 3a). We found, using a Griess
reaction assay, that silencing GSK-3 reduced the produc-
tion of NO (Fig. 3b), and using ELISA, that silencing
GSK-3 reduced the production of RANTES (Fig. 3c) but
augmented the production of IL-10 (Fig. 3d).
To further investigate the role of GSK-3b, we used cells
that overexpressed the wild-type (WT) or dominant-nega-
tive (DN) forms of GSK-3b R96A (transfection efficiency
rates: 855% and 801%, respectively) (data not shown).
Western blot analysis showed the upregulated GSK-3b
expression in the GSK-3b-transfection groups (Fig. 4a).
Overexpressing GSK-3b WT significantly (P < 005)
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Figure 1. The effects of inhibiting glycogen
synthase kinase-3 (GSK-3) on nitric oxide
(NO) production and inducible NO synthase
(iNOS) expression in lipopolysaccharide (LPS)
-stimulated microglia. (a) BV2 mouse micro-
glial cells (25 · 105) were pretreated with
10 mm of GSK-3 inhibitor lithium chloride
(LiCl) for 30 min and then treated with 1 lg/
ml of LPS for 025, 05 and 1 hr. We used
Western blotting to determine phosphorylation
of GSK-3b at Ser9 (pGSK-3b). b-Actin was the
internal control. The ratio of pGSK-3b to total
GSK-3b is shown. (b) BV2 cells and primary
rat microglial cells (3 · 104) were pretreated
with the indicated doses of GSK-3 inhibitors –
LiCl, thiadiazolidine (TDZD-8), SB216763,
SB415286, AR-A014418 (AR), 6-bromo-indiru-
bin-30-oxime (BIO) and GSK-3 inhibitor I
(GSK3i) – for 30 min and then treated with
1 lg/ml LPS for 24 hr. Cells treated with
dimethyl sulphoxide were the negative control.
After the supernatant had been collected, we
determined NO production [referred to as ‘the
detection of nitrite (NO2
))’] using Griess
reagent as described in the Materials and
methods. Sodium nitrite (NaNO2) was used
for the standard calculation of nitrite concen-
tration. The data are means ± SD obtained
from three individual experiments. *P < 005
compared to the LPS group. (c and d) Cells
were treated with LPS with or without and
LiCl (10 mm) or BIO (5 lm) co-treatment. We
used Western blotting, immunostaining, and
then flow cytometric analysis, to determine
iNOS protein expression. b-Actin was the
internal control. The ratio of iNOS to b-actin
is shown. Data shown are representative of
three individual experiments. The percentages
of positive cells are means ± SD.
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increased the production of LPS-induced NO (Fig. 4b)
and RANTES (Fig. 4c) but decreased the production of
IL-10 (Fig. 4d). Immunocytochemical staining yielded
similar results: cells overexpressing GSK-3b WT but not
GSK-3b DN showed higher iNOS protein expression
(data not shown). In contrast, cells overexpressing GSK-
3b DN showed a significant (P < 005) decrease in NO
(Fig. 4b) and RANTES (Fig. 4c) and a significant
(P < 005) increase in IL-10 (Fig. 4d). These results
strongly indicated the indispensable role of GSK-3 in
LPS-induced NO and RANTES production. In addition,
inhibiting GSK-3 caused IL-10 overproduction under LPS
stimulation.
Inhibiting GSK-3 reduced NO and RANTES by
upregulating IL-10
To investigate whether the mechanisms that inhibit
GSK-3 reduce NO and RANTES production, we further
examined the effects of upregulated IL-10. Conditional
medium obtained from LPS-treated cells in which GSK-3
had been inhibited caused a decrease in NO production
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Figure 2. The effects of inhibiting glycogen
synthase kinase-3 (GSK-3) on RANTES and
interleukin-10 (IL-10) expression in lipopoly-
saccharide (LPS)-stimulated microglia. BV2
mouse microglial cells (3 · 104) were pretreat-
ed with LiCl (10 mm) or 6-bromo-indirubin-
30-oxime (BIO; 5 lm) for 30 min and then
treated with LPS (1 lg/ml). (a) After collecting
the supernatant 6-hr post-treatment, we deter-
mined cytokine and chemokine production
using an antibody array as described in the
Materials and methods. The expression of
RANTES is labelled with a dotted column as
indicated. We used densitometry to quantify
the relative signal intensity. The data are
means ± SD obtained from four dots in dupli-
cate experiments. (b and c) Enzyme-linked
immunosorbent assay was used to determine
the time kinetics and dose–response of LiCl
and BIO on RANTES and IL-10 production.
The data are means ± SD obtained from three
individual cultures. *P < 005 compared to the
LPS group. (d) For the indicated time periods,
we used reverse transcription polymerase chain
reaction to determine RANTES and IL-10 mes-
senger RNA expression. b-Actin was the inter-
nal control. The ratio of RANTES or IL-10 to
b-actin is shown. Data shown are representa-
tive of three individual experiments.
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(data not shown). We further found that anti-IL-10
neutralizing antibodies, but not control IgG, significantly
(P < 005) reversed the downregulation of NO (Fig. 5a)
and RANTES (Fig. 5b) in LPS-treated cells while GSK-3
was inactivated by inhibitors (Fig. 5a,b, left panel) and
siRNA (Fig. 5a,b, right panel). These results strongly
showed that IL-10 was critical for inhibiting GSK-3-
induced NO and RANTES downregulation.
Inhibiting GSK-3 induced IL-10 upregulation through
a mechanism involving Akt-, ERK-, p38 MAPK- and
NF-jB-regulated pathways followed by activation of
transcription factors
Interleukin-10 production is positively regulated by LPS-
activated phosphatidylinositol 3-kinase (PI3-kinase)/Akt,
MAPK/ERK (MEK)/ERK, p38 MAPK and several tran-
scription factors including NF-jB, Sp1, C/EBPb, C/EBPd
and CREB.23,24,46–49 To investigate the mechanism of
IL-10 upregulation by inhibiting GSK-3, using selective
kinase inhibitors LY294002 (specific for PI3-kinase),
PD98059 (specific for MEK), SB203580 (specific for p38
MAPK) and PDTC (specific for NF-jB), we first showed
that all of the inhibitors significantly (P < 005) reduced
the production of IL-10 in LPS-treated cells with or with-
out LiCl or BIO co-treatment (Fig. 6a). To further con-
firm the effects of GSK-3 inhibition, we determined the
activation of these proteins. Western blot analysis showed
that treating cells with BIO showed an increase on phos-
phorylation of Akt (Ser473), ERK (Thr202/Tyr204) and
p38 MAPK (Thr180/Tyr182) (Fig. 6b). To identify the
effects of inhibiting GSK-3 on LPS-activated transcription
factors, we treated cells with LPS and with or without
GSK-3 inhibitors. Western blot analysis showed the
higher nuclear translocation of C/EBPb (018 with LPS
only versus 086 with LPS + LiCl and 096 with
LPS + BIO), C/EBPd (016 with LPS only versus 027
with LPS + LiCl and 033 with LPS + BIO), CREB (083
with LPS only versus 109 with LPS + LiCl and 123 with
LPS + BIO) and NF-jB p65 (058 with LPS only versus
112 with LPS + LiCl and 108 with LPS + BIO) in LPS-
treated cells 3 hr after GSK-3-inhibitor co-treatment
(Fig. 6c). However, there were no changes on Sp1 nuclear
translocation (097 with LPS only versus 101 with
LPS + LiCl and 096 with LPS + BIO). These results indi-
cated that inhibiting GSK-3 increased the production of
LPS-induced IL-10 by PI3-kinase/Akt-, MEK/ERK- and
p38 MAPK-regulated pathways.
Discussion
In the present study, we showed that inhibiting GSK-3
reduced LPS-induced iNOS/NO biosynthesis and RAN-
TES production by triggering anti-inflammatory IL-10. In
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Figure 3. Inhibiting glycogen synthase kinase-3 (GSK-3) reduced
lipopolysaccharide (LPS)-induced nitric oxide (NO) and RANTES
but induced interleukin-10 (IL-10) production in microglia. BV2
mouse microglial cells (25 · 105) were pretreated with control
short interference RNA (siRNA; 50 nm) or GSK-3 siRNA (50 nm)
for 24 hr. The transfection efficiencies were 902% and 875%,
respectively. (a) We used Western blotting to determine GSK-3b.
b-Actin was the internal and negative control. The ratio of
GSK-3b to b-actin is shown. (b) Cells were untreated or treated
with 1 lg/ml of LPS for 24 hr. We determined NO production
using Griess reagent. (c and d) For the 6-hr treatment, we used
enzyme-linked immunosorbent assay to determine RANTES and
IL-10 production. Cells treated with LiCl and 6-bromo-indirubin-
30-oxime (BIO) were the positive controls. The data are
means ± SD obtained from three individual cultures. *P < 005
compared to the LPS group.
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addition to direct or indirect regulation on NF-jB,31–33,50
we provide evidence to demonstrate the anti-inflamma-
tory role of GSK-3 inhibition, at least in part, by upregu-
lating IL-10. Furthermore, mechanistic studies showed
that inhibiting GSK-3 caused an enhancement effect on
activation of a series of kinases and transcriptional fac-
tors, all of which were involved in IL-10 production. A
number of other studies34,35,38,40,42,51,52 have recently
reported that inhibiting GSK-3 reduced endotoxaemia-
induced tissue injury in, for example, the liver. We also
found that inhibiting GSK-3 reduced endotoxaemia-
induced septic lethality and acute renal failure (data not
shown). Therefore, we hypothesize that GSK-3 has a pro-
inflammatory role in LPS-mediated signalling and that
inhibiting GSK-3 will be beneficial in antisepsis therapy.
Progressive neurodegenerative disorders are caused by
uncontrolled neuroinflammation resulting from aging and
neurotoxicity induced by toxic agents, trauma, hypoxia/
ischaemia and systemic microbe infection including viral
and bacterial infections.53–56 Microglia, the resident innate
immune cells in the brain derived from myeloid cells,
mediate neurotoxicity by triggering the release of cyto-
toxic factors such as superoxide, NO, IL-1b, IL-6 and
TNF-a.15 Treating mice with Gram-negative bacterial
endotoxin causes neurodegenerative-like disorders such as
Parkinson’s disease and Alzheimer’s disease.57,58 Lipopoly-
saccharide causes dopaminergic neurotoxicity following
microglia activation15,19,43,57 so inflammatory activation
of microglia is the pathogenic target of endotoxin stimu-
lation in neuropathy. Previous studies found, after inhib-
iting GSK-3, that it had an essential role in TNF-a-,
endotoxaemia-, zymosan- and ovalbumin-induced inflam-
mation.31–42,51 Inhibiting GSK-3 downregulated the pro-
duction of the proinflammatory cytokines TNF-a,
interferon-c, IL-6 and IL-12p40.31 Using antibody array
analysis (Fig. 2), we showed that inhibiting GSK-3 down-
regulated the chemokine RANTES and blocked iNOS/NO
biosynthesis (Fig. 1). RANTES is important for recruiting
monocytes and macrophages to the lung in endo-
toxaemia.59,60 Moreover, excessive NO production con-
tributes to circulatory failure in sepsis.2,6,22 The
mechanisms of GSK-3 regulation of RANTES and iNOS/
NO expression require further investigation.
Interleukin-10, one of the T helper type 2 cytokines,
confers comprehensive anti-inflammatory and antipyretic
effects.24–29,43 Previous studies31,32 found that inhibiting
GSK-3 increased IL-10 production and suppressed the
release of proinflammatory cytokines in TLR-2, TLR-4,
TLR-5 and TLR-9 agonist-treated monocytes. Addition-
ally, GSK-3 regulated interferon-c-mediated IL-10 sup-
pression, differentiation and proinflammatory activation
in dendritic cells.61–63 In the present study, treatment
with GSK-3 inhibitors, siRNA and dominant-negative
mutant showed similar results (Figs 3 and 4). Our
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Figure 4. The effects of glycogen synthase kinase-3 (GSK-3) on nitric
oxide (NO), RANTES and interleukin-10 (IL-10) production in lipo-
polysaccharide (LPS)-stimulated microglia. BV2 mouse microglial
cells (25 · 105) were transfected with pcDNA3.1 vector alone (con-
trol), pcDNA3.1-GSK-3b wide-type (GSK-3b WT) or dominant-
negative form (GSK-3b DN) for 24 hr. (a) After the cells had been
treated with LPS (1 lg/ml) for 24 hr, we used Western blotting to
determine GSK-3b expression. b-Actin was the internal control. The
ratio of GSK-3b to b-actin is shown. (b) We determined NO pro-
duction using Griess reagent. (c and d) For the 6-hr treatment, we
used enzyme-linked immunsorbent assay to determine RANTES and
IL-10 production. Cells treated with lipofectamine 2000 were the
negative control. The data are means ± SD obtained from three indi-
vidual experiments. *P < 005 compared to the LPS group.
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neutralization experiment showed that upregulated IL-10
was, at least in part, required to inhibit GSK-3-induced
NO and to downregulate RANTES (Fig. 5). Interleukin-
10 reduced iNOS/NO biosynthesis and RANTES produc-
tion in several models of inflammation.21,23,24,29 The
mechanism that IL-10 uses is to rapidly induce transcrip-
tion of the suppressor of cytokine signalling 3 (SOCS3),
which provides negative feedback regulation against
inflammatory activation.24,29
Exogenous administration and transgenic expression of
IL-10 have been used to treat a variety of inflammatory
diseases, autoimmune diseases and allograft rejection in
patients and experimental models.25–30 Previous studies
further demonstrated the protective effect of IL-10 on
LPS-induced microglia activation followed by dopaminer-
gic neurotoxicity.43 In the present study, we provide
evidence that inhibiting GSK-3 upregulates endogenous
IL-10 production and has an anti-inflammatory effect.
However, the causes of IL-10 upregulation require further
investigation. In TLR signalling, GSK-3 has been reported
to regulate the activation of CREB and its DNA-binding
activity;31,32 GSK-3 does this by causing phosphorylation
at Ser129, which inactivates CREB. Because CREB is
essential for regulating IL-10 gene expression,24 it is
believed that inhibiting GSK-3 upregulates IL-10 after
CREB has been activated.31,32 Furthermore, we confirmed
the essential role of PI3-kinase/Akt, MEK/ERK, p38
MAPK and NF-jB for LPS-induced IL-10 production as
similar to previous studies.46–49 Notably, inhibiting GSK-
3-caused IL-10 upregulation is, at least in part, regulated
by Akt-, ERK-, p38 MAPK- and NF-jB (Fig. 6a). Current
studies showed that transcription factors, including
C/EBPb, C/EBPd and NF-jB, are crucial for IL-10 expres-
sion.24,47–49 We further demonstrated that inhibiting
GSK-3 increased the nuclear translocation of these tran-
scription factors (Fig. 6c). However, the mechanisms by
which inhibiting GSK-3 increased nuclear translocation of
these transcription factors need further investigation. In
addition to CREB regulation, the effects of inhibiting
GSK-3 on those factors that positively regulated IL-10
production should be further investigated.
The mechanisms of TLR-mediated GSK-3 activation
are still unclear. Protein phosphatase and Akt are the
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Figure 5. Inhibiting glycogen synthase kinase-3 (GSK-3)-reduced nitric oxide (NO) and RANTES production was blocked by anti-interleukin-10
(IL-10) in lipopolysaccharide (LPS)-stimulated microglia. BV2 mouse microglial cells (3 · 104) were pretreated with LiCl (10 mm) or 6-bromo-
indirubin-30-oxime (BIO; 5 lm) for 30 min, or GSK-3 short interference RNA (siRNA; 50 nm) for 24 hr, and then treated with 1 lg/ml of LPS
plus 1 lg/ml of anti-IL-10 neutralizing antibodies for 24 hr. (a) We determined NO production using Griess reagent. (b) We used enzyme-linked
immunsorbent assay to determine RANTES production for the 6-hr treatment. Cells treated with control immunoglobulin G (IgG) and control
siRNA were the negative controls. The data are means ± SD obtained from three individual experiments. *P < 005 compared to the control
group.
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activation.44,45 Our data showed that GSK-3 was tran-
siently activated after LPS stimulation (Fig. 1a). Further
results showed that the protein phosphatase inhibitor
okadaic acid decreased NO production in LPS-stimulated
macrophages (data not shown). The mechanisms of LPS-
induced GSK-3 activation need further investigation.
Previous studies24,29 showed that LPS caused IL-10
mRNA and IL-10 protein expression after the proinflam-
matory cytokines TNF-a, IL-1 and IL-6 and chemokines
MCP-1 and RANTES were produced. Based on all these
results, it can be hypothesized that initial LPS signalling
induces GSK-3 activation, inflammatory activation, CREB
inactivation and IL-10 inhibition, and that subsequent
LPS signalling – after GSK-3 has been inactivated and
CREB activated – induces the production of IL-10.61,62
The homeostatic process is believed to be negative feed-
back regulation. Inhibiting GSK-3 may cause the earlier
negative feedback response by upregulating IL-10 to
downregulate RANTES and iNOS/NO in the early stage
of LPS-induced inflammation.
In conclusion, our study showed that inhibiting
GSK-3 raised anti-inflammatory activities, which sug-
gests that GSK-3 is essential in LPS-induced microglial
inflammation. These results are in agreement with pre-
vious reports31,32,34–42,51,52 that the emerging actions of
GSK-3 involve inflammatory activation in several dis-
ease models. In the present study, we showed that
inhibiting GSK-3 using pharmacological and molecular
strategies dramatically downregulated iNOS/NO and




















LPS (1 μg/ml) 
LiCl (10 mM)
BIO (5 μM) 
LY294002 (10 μM) 
U0126 (10 μM) 
SB203580 (10 μM) 
PDTC (10 μM) 


















– – – – – – 






– – – – 
– 
– – – 
– – – 
– – 
– 
– – – – 
– – – 





– – – – – – – – – 
– – – – 




– – – – 






















































0·02 0·07 0·11 0·16 0·08 1·95 0·23 0·06 
0·94 0·92 1·17 1·12 0·92 0·92 0·91 0·94 




– – – – 
– 
+ + 







LPS (1 μg/ml) 












+ + + 
0·24 0·58 1·08 1·12 
1·23 1·09 0·83 0·19 
0·33 0·27 0·16 0·12 
0·96 0·86 0·18 0·15 
0·92 
Sp1-









Figure 6. The mechanisms of inhibiting glyco-
gen synthase kinase-3 (GSK-3) synergized with
lipopolysaccharide (LPS) to induce interleukin-
10 (IL-10) upregulation. (a) BV2 mouse
microglia cells (3 · 104) were pretreated with
10 lm of LY294002 to inhibit phosphatidylino-
sitol 3-kinase (PI3-K), U0126 to inhibit mito-
gen-activated protein kinase (MAPK)/
extracellular signal regulated kinase (ERK)
(MEK), SB203580 to inhibit p38 MAPK, or
PDTC to inhibit nuclear factor-jB (NF-jB),
for 05 hr and then treated with LPS (1 lg/ml)
with or without LiCl (10 mm) or 6-bromo-
indirubin-30-oxime (BIO; 5 lm) for 6 hr. We
used enzyme-linked immunosorbent assay to
determine IL-10 production. Cells treated with
dimethyl sulphoxide were used for the negative
control. *P < 005 compared to the LPS group.
(b) BV2 cells (25 · 105) were pretreated with
BIO (5 lm) for 30 min and then treated with
1 lg/ml LPS for 025, 1 and 3 hr. We used
Western blotting to determine phosphorylation
of Akt at Ser473 (pGSK-3b), ERK at Thr202/
Tyr204 (pERK) and p38 MAPK at Thr180/
Tyr182 (pp38 MAPK). b-Actin was the internal
control. The ratio of phosphorylated protein to
total protein is shown. (c) BV2 mouse micro-
glial cells (25 · 105) were pretreated with LiCl
(10 mm) or BIO (5 lm) for 05 hr and then
treated with LPS (1 lg/ml) for 3 hr. The
nuclear protein extract was prepared using a
kit as described in the Materials and methods.
We used Western blotting to determine the
nuclear translocation of transcription factors,
including Sp1, C/EBPb, C/EBPd, CREB and
NF-jB p65 subunit. b-Actin was the internal
control of cytosolic protein. The ratio of
nuclear protein to b-actin is shown.
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ability to inhibit GSK-3 suggests that it may be used as
a novel anti-inflammatory strategy against LPS-induced
neuroinflammation.
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